Midas Pharma GmbH
2 products tracked · names used in filings: Midas Pharma GmbH
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Epruvy (previously Ranibizumab Midas) ranibizumab | Authorised | 2024-09-19 |
| 🇪🇺 | Ranivisio ranibizumab | Authorised | 2022-08-25 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.